FY2025 EPS Estimates for DNTH Lowered by Cantor Fitzgerald

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Equities research analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for shares of Dianthus Therapeutics in a note issued to investors on Wednesday, May 14th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings of ($3.45) per share for the year, down from their previous forecast of ($3.16). The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share.

Several other equities research analysts have also recently commented on the stock. Guggenheim reiterated a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Robert W. Baird cut their target price on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating on the stock in a report on Tuesday, May 13th. Wedbush reissued an “outperform” rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $53.00.

Dianthus Therapeutics Price Performance

Shares of NASDAQ:DNTH opened at $19.69 on Friday. Dianthus Therapeutics has a one year low of $13.37 and a one year high of $32.27. The company has a 50 day moving average of $19.40 and a 200-day moving average of $22.11. The stock has a market cap of $632.56 million, a price-to-earnings ratio of -7.88 and a beta of 1.48.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $0.81 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Octagon Capital Advisors LP increased its position in shares of Dianthus Therapeutics by 11.0% during the first quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company’s stock worth $42,478,000 after acquiring an additional 231,500 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after acquiring an additional 618 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of Dianthus Therapeutics by 5.0% during the first quarter. Adage Capital Partners GP L.L.C. now owns 189,000 shares of the company’s stock worth $3,428,000 after acquiring an additional 9,000 shares in the last quarter. ADAR1 Capital Management LLC increased its position in shares of Dianthus Therapeutics by 3.4% during the first quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company’s stock worth $332,000 after acquiring an additional 602 shares in the last quarter. Finally, Vestal Point Capital LP increased its position in shares of Dianthus Therapeutics by 58.1% during the first quarter. Vestal Point Capital LP now owns 1,700,069 shares of the company’s stock worth $30,839,000 after acquiring an additional 625,069 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.